Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries
- PMID: 3567364
- DOI: 10.1159/000158670
Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries
Abstract
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery. In both species, VIP caused nearly complete relaxation of precontracted vessel segments. The EC50 was 1.3 +/- 0.3 X 10(-9) M (mean +/- SD) in bovine and 3.4 +/- 0.4 X 10(-9) M in human pulmonary artery. The response to VIP was not endothelium-dependent and it was not affected by either adrenergic and cholinergic blockade or by cyclooxygenase inhibition. PHI also relaxed human and bovine vessels but this related peptide was significantly less effective than VIP. We conclude that VIP is a potent inhibitor of bovine and human pulmonary artery, which appears to act directly on vascular smooth muscle. These data support the concept that VIP may be a neurotransmitter which modulates pulmonary artery tone in both man and cow.
Similar articles
-
Relaxation of isolated bovine coronary arteries by vasoactive intestinal peptide.Eur J Pharmacol. 1990 Jun 8;181(3):199-205. doi: 10.1016/0014-2999(90)90079-l. Eur J Pharmacol. 1990. PMID: 2384132
-
Relaxant effects of vasoactive intestinal peptide and bethanechol in cat intrapulmonary artery.Eur J Pharmacol. 1983 Sep 16;93(1-2):121-4. doi: 10.1016/0014-2999(83)90039-0. Eur J Pharmacol. 1983. PMID: 6138270
-
The effects of vasoactive intestinal peptide (VIP) antagonists, and VIP and peptide histidine isoleucine antisera on non-adrenergic, non-cholinergic relaxations of tracheal smooth muscle.Br J Pharmacol. 1989 Mar;96(3):513-20. doi: 10.1111/j.1476-5381.1989.tb11847.x. Br J Pharmacol. 1989. PMID: 2720290 Free PMC article.
-
Effects of peptidases on non-adrenergic, non-cholinergic inhibitory responses of tracheal smooth muscle: a comparison with effects on VIP- and PHI-induced relaxation.Br J Pharmacol. 1989 Mar;96(3):521-6. doi: 10.1111/j.1476-5381.1989.tb11848.x. Br J Pharmacol. 1989. PMID: 2655804 Free PMC article.
-
Role of vasoactive intestinal peptide and peptide histidine isoleucine in the cerebral circulation.Ann N Y Acad Sci. 1988;527:378-92. doi: 10.1111/j.1749-6632.1988.tb26994.x. Ann N Y Acad Sci. 1988. PMID: 2898910 Review. No abstract available.
Cited by
-
Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.Hippokratia. 2013 Jan;17(1):12-6. Hippokratia. 2013. PMID: 23935337 Free PMC article.
-
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.J Clin Invest. 2003 May;111(9):1339-46. doi: 10.1172/JCI17500. J Clin Invest. 2003. PMID: 12727925 Free PMC article.
-
Modulation of cholinergic neural bronchoconstriction by endogenous nitric oxide and vasoactive intestinal peptide in human airways in vitro.J Clin Invest. 1993 Aug;92(2):736-42. doi: 10.1172/JCI116644. J Clin Invest. 1993. PMID: 8349813 Free PMC article.
-
Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation.Peptides. 2009 Dec;30(12):2323-9. doi: 10.1016/j.peptides.2009.08.010. Epub 2009 Aug 19. Peptides. 2009. PMID: 19698755 Free PMC article.
-
Effects of neuropeptide Y and vasoactive intestinal peptide on human venous smooth muscle in vivo.Naunyn Schmiedebergs Arch Pharmacol. 1994 Aug;350(2):194-200. doi: 10.1007/BF00241096. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 7990977